Eli Lilly Forqglope: 12% Weight Loss Results
# Eli Lilly’s Oral GLP-1 Pill Shows Promising Results in Weight Loss Trial
eli Lilly’s experimental oral GLP-1 drug, orforglipron, is demonstrating encouraging results in a Phase 3 clinical trial, potentially offering a more convenient alternative to currently available injectable weight loss medications like Wegovy and Ozempic. The trial data, presented ahead of a major medical meeting, focuses on discontinuation rates and side effects, key factors influencing physician and patient adoption.
## Key Trial Findings: Discontinuation Rates and Side Effects
A primary goal of the trial was to demonstrate a lower dropout rate compared to placebo. According to Eli Lilly’s medical director, Dr. ricks, the study successfully achieved this. “What we really want to see is that the medicine dropout rate is lower than placebo, and that’s what we saw here,” he stated, referencing discontinuation rates for any reason.
the company aimed for a dropout rate of less than 12% due to side effects, a benchmark aligned with industry experience with existing GLP-1 drugs, which typically see rates between 8% and 12%. Dr. Ricks confirmed the trial results were “right in the middle,” emphasizing that while continuation rates for chronic medications aren’t always perfect, the drug’s dropout rate aligned with expectations.
University of Florida researcher Dr. Sheer believes these discontinuation rates and side effect profiles won’t deter physicians from prescribing the oral pill.In fact,she suggests the oral formulation could *increase* prescribing rates,as some doctors are hesitant to prescribe injections due to concerns about patient education and proper governance. “They may not know how to tell patients how to use them,” she explained.
## Patient-Specific Considerations: Oral vs. Injectable GLP-1s
Prescribing decisions will ultimately be tailored to individual patient needs and preferences, alongside considerations of access and affordability, according to Dr. Almandoz. Injectable GLP-1s may remain the preferred option for patients prioritizing maximum weight loss or those with significant cardiometabolic complications – health issues stemming from cardiovascular and metabolic disorders.
However, orforglipron could be ideal for individuals who “prioritize simplicity or convenience or have these logistical challenges with injections.” This highlights the potential for the oral pill to broaden access to GLP-1 therapy for a wider range of patients.
## How Orforglipron differs from Existing GLP-1 Medications
Like Wegovy, Rybelsus, and Ozempic, orforglipron targets the GLP-1 gut hormone to promote weight loss and regulate blood sugar. Though, a crucial distinction lies in its formulation.Eli Lilly’s pill is *not* a peptide medication,meaning it’s absorbed more readily by the body. This improved absorption also eliminates the dietary restrictions currently required with Rybelsus.
Detailed trial results will be presented in September at a European medical meeting and later published in a peer-reviewed journal. Further Phase 3 trial data, including results from a study involving adults with obesity or overweight and Type 2 diabetes, will be released later this year.
## Market Potential and Competitive Landscape
Eli Lilly currently holds a roughly three-year lead over competitors developing oral GLP-1 pills, including Pfizer, AstraZeneca, Roche, Structure Therapeutics, and Viking Therapeutics.Analysts predict a ample market for GLP-1s, potentially exceeding $150 billion annually by the early 2030s. Oral GLP-1s are projected to capture a significant portion of this market, potentially reaching $50 billion in annual revenue, according to Guggenheim analyst Seamus Fernandez.
–CNBC’s Angelica Peebles contributed to this report.